LncRNA EGFR-AS1 Modulates Ferroptosis to Decrease Cervical Cancer Radiosensitivity via the m6A/IGF2BP3/APAF1 Pathway
-
By
-
Xianglong Chen
-
Jingyu Li
-
Yujie Sun
-
Zhaoyu Ye
-
Man Long
-
Junguo Bu
-
Zirong Fan
-
Zhaojing Jiang
-
March 5, 2026
-
Clinical Scorecard: LncRNA EGFR-AS1 Modulates Ferroptosis to Decrease Cervical Cancer Radiosensitivity via the m6A/IGF2BP3/APAF1 Pathway
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients with cervical cancer, particularly those with advanced stages. |
| Care Setting | |
Key Highlights
- m6A modification is implicated in the regulation of cervical cancer cell behavior.
Guideline-Based Recommendations
Diagnosis
- Assess cervical cancer stage and radiotherapy sensitivity through histological analysis.
- Incorporate lncRNA analysis in diagnosis.
Management
- Utilize radical radiotherapy for intermediate and advanced cervical cancer stages.
- Consider lncRNA analysis in treatment planning.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Investigate lncRNA and ferroptosis pathways to improve treatment outcomes, focusing on specific lncRNAs.
Clinical Best Practices
- Incorporate lncRNA analysis in treatment planning for cervical cancer using specific assays.
- Explore ferroptosis in therapeutic strategies to enhance radiotherapy efficacy.
References
